Berchuck A, et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 1996; 175:738.

Berek JS. Interval debulking of ovarian cancer: an interim measure. N Engl J Med I995; 332:675.

Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer: patient selection and review of the literature. Cancer 1996; 78:2049.

Cannistra SA, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003; 21(10 Suppl):129.

Farias-Eisner R, et al. The influence of tumor grade, distribution and extent of carcinomatosis in minimal residual epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994; 55:108.

Frank TS, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16:2417.

Hoskins WJ, et al. The influence of cytoreductive surgery on recurren- ce-free interval and survival in small volume state III epithelial ovarian cancer: a Gynecology Oncology Group Study. Gynecol Oncol 1992; 47:159.

Kalil NG, McGuire WP. Chemotherapy for advanced epithelial ovarian carcinoma. Best Pract Res Clin Obstet Gynaecol 2002; 16:553.

Markman M, et al. Gynecologic Oncology Group Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclita- xel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21:2460.

Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer. J Reprod Med 2001; 46:621.

NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment and follow-up. JAMA 1995; 273:491.

Struewing JP, et al. The risk of cancer associated with specific mutations of BRCA1 and RCA2 among Ashkenazi Jews. N EnglJ Med\991\ 336:1401.

Van der Burg MEL, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332:629.